ArticleInfectious diseases & clinical microbiology2025
Risk Factors for Mortality in Patients Treated with Colistin Monotherapy for Carbapenem-Resistant
Article in Infectious diseases & clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Epidemiology of Carbapenem-ResistantJournal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Colistin is a critical antibiotic used to treat infections caused by carbapenem-resistant Gram-negative organisms, including carbapenem-resistant Materials and Methods: A retrospective cohort study was conducted at Nakornping Hospital, including adult patients treated with intravenous colistin monotherapy between January 2015 and October 2021. Univariate and multivariate analyses were performed to identify independent predictors of 30-day mortality. Results: A total of 223 patients were included in the study. The 30-day mortality rate was 37.22%. Univariate analysis found that age, malignancy, Charlson Comorbidity Index score, nephrotoxicity, mechanical ventilation, septic shock, and intensive care unit status were significantly associated with an increased risk of mortality. However, the total dose of colistin was associated with a decreased risk of mortality. In multivariate analysis, malignancy, nephrotoxicity, mechanical ventilation, and septic shock were significantly associated with an increased risk of mortality. Conversely, the total dose of colistin was associated with a decreased risk of mortality. Conclusion: This study highlighted the importance of considering key risk factors in the management of CRAB infections treated with colistin monotherapy. Identifying patients at higher risk of mortality can guide treatment decisions and improve outcomes in this challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.